Pulmonary arterial hypertension: A rare disease that encourages the development of multiple treatments

Expert Opinion on Orphan Drugs

Volumn 2, Issue 11, 2014, Pages 1137-1145

  Norman, Peter ^a  

^a Norman Consulting   (United Kingdom)

Author keywords

Endothelin antagonist; Guanylate cyclase; IP receptor agonist; Nitric oxide; PDE5 inhibitor; Pulmonary arterial hypertension

Indexed keywords

2 METHOXYESTRADIOL; AMBRISENTAN; ANGIOTENSIN[1-7]; ANTIHYPERTENSIVE AGENT; BERAPROST; BOSENTAN; CICLETANINE; DICHLOROACETIC ACID; ELAFIN; IFERANSERIN; ILOPROST; IMATINIB; LISURIDE; MACITENTAN; ORPHAN DRUG; PROSTACYCLIN; PRX 08066; SELEXIPAG; SEROTONIN 2 ANTAGONIST; SILDENAFIL; SODIUM NITRITE; TADALAFIL; TERGURIDE; TREPROSTINIL; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; CLINICAL FEATURE; DRUG EFFICACY; DRUG MARKETING; DYSPNEA; ENDOTHELIAL DYSFUNCTION; EUROPE; FAINTNESS; FATIGUE; HUMAN; NONHUMAN; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL ACTIVITY; PREVALENCE; PULMONARY HYPERTENSION; RARE DISEASE; REVIEW; SEX DIFFERENCE; SUSTAINED RELEASE FORMULATION; THORAX PAIN; UNITED STATES; VASODILATATION;

EID: 84910104452     PISSN: None     EISSN: 21678707     Source Type: Journal    
DOI: 10.1517/21678707.2014.924851     Document Type: Review

References (57)

1. Norman P. Orphan drug approvals in Europe since 2001: an analysis by indication. Exp Opin Orphan Drugs 2013;1(2):131-9
2. Kirson NY, Birnbaum HG, Ivanova JI, et al. Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States. Curr Med Res Opin 2011;27(9):1763-8 • Up-to-date assessment of US prevalence of pulmonary arterial hypertension.
3. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-30 • One of the first studies to highlight the benefits of national registries.
4. Simonneau G, Robbins I, Beghetti M, et al. "Updated Clinical classification of pulmonary hypertension". J Am Coll Cardiol 2009;54(1 Suppl):S43-54
5. Peacock AJ, Murphy NF, McMurray JJ, et al. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007;30(1):104-9 •• Valuable review.
6. Galiè N, Hoeper MM, Humbert H, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009;30:2493-537
7. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation 2009;119:2250-94
8. Tuder RM, Stacher E, Robinson J, et al. Pathology of pulmonary hypertension. Clin Chest Med 2013;34(4):639-50 •• Up-to-date review of the disease pathology.
9. Channick R, Preston I, Klinger JR. Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors. Clin Chest Med 2013;34(4):811-24 • Review of approved oral therapies.
10. McLaughlin VV, Palevsky HI. Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension. Clin Chest Med 2013;34(4):825-40 • Review of approved prostanoid therapies.
11. Simonneau G, Galiè N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43(12 Suppl):5S-12
12. Frost AE, Badesch DB, Barst RJ, et al. The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest 2011;139:128-37
13. McGoon MD, Benza RL, Escribano-Subias P, et al. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol 2013;24:62(25 Suppl):D51-9
14. United Therapeutics Corp, Cowen and Company 34th Annual Health Care Conference. 2014. Available from: http://files.shareholder.com/downloads/UTHR/2999876736x0x732028/12865ae6-c58a-43ba-a2ac-f5fb72352018/UTHR%20Cowen%202014.pdf
15. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351(14):1425-36 •• Excellent overview of the state of the art in 2004.
16. Galiè N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. J Am Coll Cardiol 2013;62(25 Suppl):D60-72 •• The latest proposed treatment algorithm.
17. Frumkin LR. The pharmacological treatment of pulmonary arterial hypertension. Pharmacol Rev 2012;64(3):583-620 •• Comprehensive review encompassing approved and unapproved treatments.
18. Sitbon O, Morrell N. Pathways in pulmonary arterial hypertension: the future is here. Eur Respir Rev 2012;21(126):321-7
19. Higenbottam T, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984;1:1046-7
20. Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008;31(4):891-901
21. Simonneau G, Barst RJ, Galie N, et al. Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analog, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4
22. Channick RN, Voswinckel R, Rubin LJ. Inhaled treprostinil: a therapeutic review. Drug Des Devel Ther 2012;6:19-28
23. Tapson VF, Torres F, Kermeen F, et al. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C study): a randomized controlled trial. Chest 2012;142(6):1383-90
24. Olschewski H, Simonneau G, Galie N, et al. Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9
25. Stiebellehner L, Petkov V, Vonbank K, et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 2003;123(4):1293-5
26. Rosenzweig EB. Tadalafil for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 2010;11(1):127-32
27. Udeoji DU, Schwarz ER. Tadalafil as monotherapy and in combination regimens for the treatment of pulmonary arterial hypertension. Ther Adv Respir Dis 2013;7(1):39-49
28. Larche NE, Mousa SA. Riociguat for the management of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. Drugs Today (Barc) 2013;49(12):761-8
29. Steiner MK, Preston IR. Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension. Vasc Health Risk Manag 2008;4(5):943-53
30. Dupuis J, Hoeper MM. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 2008;31(2):407-15
31. Simonneau G, Galiè N, Jansa P, et al. Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients. Int J Cardiol 2014;172(2):332-9
32. Valerio CJ, Coghlan JG. Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient. Vasc Health Risk Manag 2009;5:607-19
33. Cohen H, Chahine C, Hui A, Mukherji R. Bosentan therapy for pulmonary arterial hypertension. Am J Health Syst Pharm 2004;61(11):1107-19
34. Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008;327(3):736-45
35. Dingemanse J, Sidharta PN, Maddrey WC, et al. Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Expert Opin Drug Saf 2014;13(3):391-405
36. Waxman AB. A review of sitaxsentan sodium in patients with pulmonary arterial hypertension. Vasc Health Risk Manag 2007;3(1):151-7
37. Croxtall JD, Keam SJ. Ambrisentan. Drugs 2008;68(15):2195-204
38. Ben-Yehuda O, Pizzuti D, Brown A, et al. Long-term hepatic safety of ambrisentan in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2012;60(1):80-1
39. Clinicaltrials.gov. Acute dosing of MK-8892 in participants with pulmonary arterial hypertension (PAH) (MK-8892-003). 2013. Available from: http://clinicaltrials.gov/ct2/show/NCT01934647
40. Kunieda T, Nakanishi N, Matsubara H, et al. Effects of long-acting beraprost sodium (TRK-100STP) in Japanese patients with pulmonary arterial hypertension. Int Heart J 2009;50(4):513-29
41. Skoro-Sajer N, Lang IM. Selexipag for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother 2014;15(3):429-36
42. Leuchte HH, Baezner C, Baumgartner RA, et al. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 2008;32(5):1289-94
43. Parsley EL, Husaini A, Masamune H, et al. Inhaled sodium nitrite: results of multiple ascending dose studies including pharmacodynamic interaction with sildenafil in normal healthy volunteers. Am J Respir Crit Care Med 2012;185:A4800
44. Parsley EL, Masamune H, Hoye WL, et al. Nebulized inhaled nitrite (AIR001) for pulmonary arterial hypertension: studies to determine safety, pharmacokinetics, and maximum tolerated dose, lack of pharmacodynamic interaction with sildenafil and optimal nebulizer device. Nitric Oxide 2013;31(1):S41-2
45. MacLean MR, Herve P, Eddahibi S, Adnot S. 5-hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br J Pharmacol 2000;131:161-8
46. Launay JM, Herve P, Peoc'h K, et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 2002;8:1129-35
47. Ghofrani HA, Al-Hiti H, Vonk-Noordegraaf A, et al. Proof-of-concept study to investigate the efficacy, hemodynamics and tolerability of terguride vs. placebo in subjects with pulmonary arterial hypertension: results of a double blind, randomised, prospective phase IIa study. Am J Respir Crit Care Med 2012;185:A2496
48. Ventrus Biosciences. Method for treating pulmonary arterial hypertension. US8324247; 2012
49. Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013;127(10):1128-38
50. Waxman AB, Lawler L, Cornett G. Cicletanine for the treatment of pulmonary arterial hypertension. Arch Intern Med 2008;168(19):2164-6
51. Waxman AB, Lawler L. Cicletanine therapy is well tolerated in patients with advanced pulmonary arterial hypertension (PAH). Am J Respir Crit Care Med 2009;179:A3353
52. Tofovic SP. Estrogens and development of pulmonary hypertension: interaction of estradiol metabolism and pulmonary vascular disease. J Cardiovasc Pharmacol 2010;56(6):696-708
53. Stacpoole PW. The dichloroacetate dilemma: environmental hazard versus therapeutic goldmine - both or neither? Environ Health Perspect 2011;119(2):155-8
54. Shenoy V, Ferreira AJ, Qi Y, et al. The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2010;182(8):1065-72
55. Alam SR, Newby DE, Henriksen PA. Role of the endogenous elastase inhibitor, elafin, in cardiovascular injury: from epithelium to endothelium. Biochem Pharmacol 2012;83:695-704
56. Nickel NP, Wang L, Li CG, et al. The elastase inhibitor Elafin restores endothelial cell homeostasis in pulmonary arterial hypertension and attenuates vascular remodeling in the sugen/hypoxia rat model. Am J Respir Crit Care Med 2013;187:A1031
57. Buckley MS, Staib RL, Wicks LM. Combination therapy in the management of pulmonary arterial hypertension. Int J Clin Pract Suppl 2013(179):13-23 •• Good meta analysis of a potential means of improving disease treatment.